Cytokinetics, Incorporated - Product Pipeline Review - 2012

Global Markets Direct, September 2012, Pages: 113

Cytokinetics, Incorporated – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Cytokinetics, Incorporated - Product Pipeline Review - 2012” provides data on the Cytokinetics, Incorporated’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Cytokinetics, Incorporated’s corporate website, SEC filings, investor presentations and featured press releases, both from Cytokinetics, Incorporated and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Cytokinetics, Incorporated - Brief Cytokinetics, Incorporated overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cytokinetics, Incorporated human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Cytokinetics, Incorporated with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Cytokinetics, Incorporated’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Cytokinetics, Incorporated’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Cytokinetics, Incorporated in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Cytokinetics, Incorporated’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Cytokinetics, Incorporated.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Cytokinetics, Incorporated and identify potential opportunities in those areas.

2
List of Tables 5
List of Figures 6
Cytokinetics, Incorporated Snapshot 7
Cytokinetics, Incorporated Overview 7
Key Information 7
Key Facts 7
Cytokinetics, Incorporated – Research and Development Overview 8
Key Therapeutic Areas 8
Cytokinetics, Incorporated – Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products – Monotherapy 12
Cytokinetics, Incorporated – Pipeline Products Glance 13
Cytokinetics, Incorporated Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Cytokinetics, Incorporated – Early Stage Pipeline Products 15
Pre-Clinical Products/Combination Treatment Modalities 15
Cytokinetics, Incorporated – Drug Profiles 16
CK-2018488 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
CK-2018509 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
CK-2018571 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CK-2019165 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CK-2066260 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
GSK-923295 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ispinesib mesylate 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Myosin Inhibitor 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
omecamtiv mecarbil 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SB-743921 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
tirasemtiv 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Cytokinetics, Incorporated – Pipeline Products by Route of Administration 35
Cytokinetics, Incorporated – Pipeline Products By Mechanism of Action 36
Cytokinetics, Incorporated – Recent Pipeline Updates 37
Cytokinetics, Incorporated - Dormant Projects 43
Cytokinetics, Incorporated – Company Statement 44
Cytokinetics, Incorporated – Locations And Subsidiaries 45
Head Office 45
Cytokinetics, Incorporated, Recent Developments 46
Cytokinetics, Incorporated- Press Release 46
Jul 26, 2012: Cytokinetics Announces Heart Failure Program Update 46
Jun 12, 2012: Cytokinetics Announces Publication Of Phase II Evidence Of Effect Study Of CK-2017357 In Journal Amyotrophic Lateral Sclerosis 47
May 24, 2012: Cytokinetics Opens Second Cohort In Phase IIb Clinical Trial Of Intravenous Omecamtiv Mecarbil In Patients With Acute Heart Failure 49
Apr 25, 2012: Cytokinetics Announces Encouraging Results From Two Phase II Clinical Trials Evaluating CK-2017357 In Patients With Amyotrophic Lateral Sclerosis 50
Apr 19, 2012: Cytokinetics's Skeletal Muscle Activator Receives Fast Track Designation From FDA 52
Apr 18, 2012: Cytokinetics To Present Clinical Trial Data Of CK-2017357 At Annual Meeting Of American Academy Of Neurology 53
Mar 06, 2012: Cytokinetics's CK-2017357 Receives Orphan Medicinal Product Designation From EMA For Treatment of Amyotrophic Lateral Sclerosis 54
Mar 05, 2012: Cytokinetics Announces Publication Of Preclinical Research Data Of CK-2017357 In Journal Nature Medicine 54
Feb 21, 2012: Cytokinetics Announces Initiation Of Phase I Clinical Trial Of Oral Formulations Of Omecamtiv Mecarbil In Healthy Volunteers 56
Nov 30, 2009: Cytokinetics Announces Clinical Trial Data Regarding SB-743921 To Be Presented At The 2009 American Society Of Hematology Annual Meeting And Exposition 57
Nov 30, 2009: Cytokinetics To Present Non-Clinical Data Relating To CK-2017357 At The 5th Cachexia Conference 57
Nov 09, 2009: Cytokinetics Announces Advancement Of CK-2017357 In Phase I Clinical Trials 58
Oct 12, 2009: Cytokinetics, GSK Terminate Collaboration, License Agreement 59
Jun 18, 2009: Cytokinetics Announces The Initiation Of A First-Time-In-Humans, Phase I Clinical Trial Of CK-2017357 60
Jun 02, 2009: Cytokinetics Presents Clinical Data Relating To Ispinesib In Patients With Metastatic Breast Cancer At The 2009 Annual Meeting Of The American Society Of Clinical Oncology 61
Jun 01, 2009: Cytokinetics Announces Non-Clinical Data Relating To GSK-923295 Presented At The 2009 Annual Meeting Of The American Society Of Clinical Oncology 62
May 30, 2009: Cytokinetics Presents Clinical Data Relating To SB-743921 In Patients With Non-Hodgkin Or Hodgkin Lymphoma At The 2009 Annual Meeting Of The American Society Of Clinical Oncology 63
May 26, 2009: Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452 64
Apr 22, 2009: Cytokinetics Announces Non-clinical Data Relating To GSK-923295 Presented At The 2009 American Association Of Cancer Research Annual Meeting 64
Apr 20, 2009: Cytokinetics Announces Non-Clinical Data Relating To CK-2017357 Presented At The 2009 Experimental Biology Conference 65
Mar 04, 2009: Cytokinetics Announces Non-clinical Data Relating To Its Skeletal Muscle Contractility Program Presented At The Biophysical Society 53rd Annual Meeting 66
Financial Deals Landscape 68
Cytokinetics, Incorporated, Deals Summary 68
Cytokinetics, Incorporated, Pharmaceuticals & Healthcare, Deal Details 70
Partnerships 70
Cytokinetics Extends Research Agreement With GlaxoSmithKline 70
Cytokinetics Extends Its Research Collaboration With GlaxoSmithKline 71
Cytokinetics Signs Strategic Agreement With Amgen 73
Cytokinetics Extends Research Collaboration With GlaxoSmithKline 74
Licensing Agreements 78
Amgen Enters Into A Licensing Agreement With Cytokinetics 78
Cytokinetics Amends Licensing Agreement With GlaxoSmithKline 79
Equity Offering 82
Cytokinetics Prices Public Offering Of Common Stock And Warrants For $42.5 Million 82
Cytokinetics Prices Public Offering Of Series B Convertible Preferred Stock And Warrants For $17.5 Million 84
Cytokinetics Announces Public Offering Of $20 Million 86
Cytokinetics Completes Private Placement Of Common Stock For $8 Million 88
Cytokinetics Completes Private Placement Of Series A Convertible Preferred Stock For $12.1 Million 90
Cytokinetics Completes Registered Direct Offering Of $14 Million 92
Cytokinetics Completes Private Placement Of $6.9 Million 94
Cytokinetics Completes Private Placement Of $1.8 Million 96
Cytokinetics Completes Private Placement Of $7.8 Million 98
Cytokinetics Completes Private Placement Of $33 Million 100
Cytokinetics Completes Registered Direct Offering Of $37 Million 102
Cytokinetics Completes Private Placement Of $6.4 Million 104
Cytokinetics Completes Private Placement Of $5.6 Million 106
Cytokinetics Completes Private Placement Of $4.9 Million 108
Cytokinetics Completes Private Placement Of $33 Million 110
Appendix 112
Methodology 112
Coverage 112
Secondary Research 112
Primary Research 112
Expert Panel Validation 112
Contact Us 113
Disclaimer 113

List of Tables
Cytokinetics, Incorporated, Key Information 7
Cytokinetics, Incorporated, Key Facts 7
Cytokinetics, Incorporated – Pipeline by Indication, 2012 9
Cytokinetics, Incorporated – Pipeline by Stage of Development, 2012 11
Cytokinetics, Incorporated – Monotherapy Products in Pipeline, 2012 12
Cytokinetics, Incorporated – Phase II, 2012 13
Cytokinetics, Incorporated – Phase I, 2012 14
Cytokinetics, Incorporated – Pre-Clinical, 2012 15
Cytokinetics, Incorporated – Pipeline By Route of Administration, 2012 35
Cytokinetics, Incorporated – Pipeline Products By Mechanism of Action, 2012 36
Cytokinetics, Incorporated – Recent Pipeline Updates, 2012 37
Cytokinetics, Incorporated - Dormant Developmental Projects,2012 43
Cytokinetics, Incorporated, Deals Summary 68
Cytokinetics Extends Research Agreement With GlaxoSmithKline 70
Cytokinetics Extends Its Research Collaboration With GlaxoSmithKline 71
Cytokinetics Signs Strategic Agreement With Amgen 73
Cytokinetics Extends Research Collaboration With GlaxoSmithKline 74
Amgen Enters Into A Licensing Agreement With Cytokinetics 78
Cytokinetics Amends Licensing Agreement With GlaxoSmithKline 79
Cytokinetics Prices Public Offering Of Common Stock And Warrants For $42.5 Million 82
Cytokinetics Prices Public Offering Of Series B Convertible Preferred Stock And Warrants For $17.5 Million 84
Cytokinetics Announces Public Offering Of $20 Million 86
Cytokinetics Completes Private Placement Of Common Stock For $8 Million 88
Cytokinetics Completes Private Placement Of Series A Convertible Preferred Stock For $12.1 Million 90
Cytokinetics Completes Registered Direct Offering Of $14 Million 92
Cytokinetics Completes Private Placement Of $6.9 Million 94
Cytokinetics Completes Private Placement Of $1.8 Million 96
Cytokinetics Completes Private Placement Of $7.8 Million 98
Cytokinetics Completes Private Placement Of $33 Million 100
Cytokinetics Completes Registered Direct Offering Of $37 Million 102
Cytokinetics Completes Private Placement Of $6.4 Million 104
Cytokinetics Completes Private Placement Of $5.6 Million 106
Cytokinetics Completes Private Placement Of $4.9 Million 108
Cytokinetics Completes Private Placement Of $33 Million 110

List of Figures
Cytokinetics, Incorporated – Pipeline by Indication, 2012 9
Cytokinetics, Incorporated – Pipeline by Stage of Development, 2012 11
Cytokinetics, Incorporated – Monotherapy Products in Pipeline, 2012 12
Cytokinetics, Incorporated – Pipeline By Route of Administration, 2012 35
Cytokinetics, Incorporated - Pipeline Products By Mechanism of Action, 2012 36

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• eBay - Strong Execution
• Scientific Games Corporation - Company Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• SunGard - Profile - US
• Ixia - Company Analysis
• Insight into Samsung Electronics' Notebook PC Business Model
• US - Accenture - Company Profile